AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03884764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ganglion impar denervation
Description: patients with chronic pelvic pain due to chronic prostatitis will receive ganglion impar denervationand and the patients will be followed for 6 months to assess pain severity ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
Study NCT01314729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiber-reinforced-composite retainer
Description: this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment
Study NCT01314729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Composite-wire retainer
Description: this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
Study NCT03406663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose, > 4.4 and ≤ 5.6 mmol/L, no change, \< 4.4 mmol/L, reduce 1 unit of Gla-300 dose
Study NCT03406663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Fasting SMPG (median of the last 3 days including current day) in the range of~* 7.8 mmol/L, increase 6 units of Gla-300 dose, > 5.6 and \< 7.8 mmol/L, increase 3 units of Gla-300 dose, > 4.4 and ≤ 5.6 mmol/L, no change,~* 3.3 and \< 4.4 mmol/L, reduce 3 units of Gla-300 dose, \< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator
Study NCT04155749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anitocabtagene-autoleucel
Description: Chimeric Antigen Receptor T cells
Study NCT02290184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PilAm Go4Health Weight-loss Program
Description: This is a 3-month lifestyle intervention program promoting weight loss through physical activity and health diet using a mobile health application (app), pedometer to track daily step-counts, and social networking (in-person and virtual social networking through Facebook) to reduce risks for metabolic syndrome in Filipino Americans with type 2 diabetes on metformin. Subjects will be asked: 1) to use a mobile app diary every day to input their weight, and calories (food and drink intake) and 2) wear a pedometer everyday to monitor their physical activity (step-counts).
Study NCT02290184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: This is a 3-month active control using a pedometer only without any education related to wt loss, physical activity, health eating, or tracking healthy behaviors
Study NCT05968235 — intervention group
Intervention type: OTHER
Intervention: Collecting blood samples
Description: Peripheral blood was collected from the study subjects and blood glucose, glycosylated hemoglobin, triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein levels were measured in the peripheral blood.
Study NCT04103008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Speckle tracking echocardiography
Description: assess left ventricular function on admission and after 40 days
Study NCT01692574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Modification for Weight Loss
Study NCT01692574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior Modification for Weight Loss
Study NCT01692574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Approach to Weight Loss
Study NCT01692574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy for Depression
Study NCT01692574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavior Therapy for Depression
Study NCT01692574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depression Support and Education
Study NCT00633659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemospan (MP4OX)
Description: 250 mL of Hemospan (MP4OX)
Study NCT00633659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voluven (HES 130/0.4)
Description: 250 mL of Voluven (HES 130/0.4) solution
Study NCT00724945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: multifocal contact lens
Study NCT00724945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: multifocal contact lens
Study NCT04161196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsil pillars suturing
Description: The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
Study NCT04161196 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: tonsillectomy without tonsil pillars suturing
Description: tonsillectomy without The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
Study NCT02402062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 + Sunitinib
Description: Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle.
Study NCT01577914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Tablets USP 12.5 mg
Description: 12.5mg tablet once a day
Study NCT01577914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: 12.5mg tablet once a day
Study NCT01994031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome injection
Study NCT01994031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Study NCT02213783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem
Description: Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
Study NCT02213783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
Study NCT03994939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together (FTT)
Description: FTT is an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative SRH outcomes in young adolescents (aged 10 to 14). The FTT intervention has been delivered with efficacy in multiple settings, including schools and clinics (Guilamo-Ramos et al., 2011a; Guilamo-Ramos et al., 2011b).
Study NCT01531920 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: alcohol + placebo
Description: Part A alcohol + placebo
Study NCT01531920 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: alcohol + perampanel
Description: Part A: alcohol + perampanel
Study NCT01531920 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: perampanel + alcohol
Description: Part B: perampanel + alcohol
Study NCT01531920 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo + alcohol
Description: Part B: placebo + alcohol
Study NCT01066364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam Hcl
Description: 3.75 gm/day (six 675 mg tablets)
Study NCT01066364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colesevelam Hcl
Description: 3.75 gm/day (six 675 mg tablets)
Study NCT02079571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut water
Description: 250 ml Coconut water for each subject
Study NCT02079571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger tea
Description: 250 ml for each subject
Study NCT01203384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5074 1x
Description: oral tablet, 1x, once a day in the morning for 14 days
Study NCT01203384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5074 2x
Description: oral tablet, 2x, once a day in the morning for 14 days
Study NCT01203384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5074 3x
Description: oral tablet, 3x, once a day in the morning for 14 days
Study NCT01203384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, placebo, once a day in the morning for 14 days
Study NCT02834468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEX Combined With RTX, CSA and IVIG
Description: The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
Study NCT03740750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermacare heat wraps
Description: low level continuous heat wrap
Study NCT03740750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: electrical stimulation
Study NCT03740750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham heat
Description: expended heat wrap
Study NCT03740750 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham heat
Description: expended heat wrap
Study NCT03740750 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham Tens
Description: tens applied but unit not turned on
Study NCT03740750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham Tens
Description: tens applied but unit not turned on
Study NCT00622648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 40 mg once daily for 6 to 14 days (10 ± 4 days)
Study NCT00622648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
Study NCT02195752 — intervention group
Intervention type: OTHER
Intervention: Compounded Pain Cream
Description: All patients will have been prescribed a topical pain cream prepared by a qualified compounding pharmacy
Study NCT03964961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional massage
Description: It's a massage combined with a stretching of the muscles.
Study NCT03964961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional massage
Description: It's a regular massage made with the therapist's hands.
Study NCT02187471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 15 mg QD or BID; tablet for oral use
Study NCT02187471 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin
Description: Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
Study NCT02187471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablet for oral use, matching DS-5565 tablet
Study NCT02187471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet for oral use, matching DS-5565 tablet
Study NCT02187471 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo tablet
Description: Placebo tablet for oral use, matching DS-5565 tablet
Study NCT02187471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule for oral use, matching pregabalin capsule
Study NCT03667287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair of parastomal hernia
Description: Surgical repair of symptomatic parastomal hernia.
Study NCT03667287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair of parastomal hernia
Description: Surgical repair of symptomatic parastomal hernia.
Study NCT02187471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule for oral use, matching pregabalin capsule
Study NCT01925417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBX2660 (microbiota suspension)
Study NCT03320811 — intervention group
Intervention type: OTHER
Intervention: Data record
Study NCT04945811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Interlukein 6 and procalcitonin serum levels
Description: Blood tests
Study NCT01147458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834
Description: 100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
Study NCT01147458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834 placebo
Description: Matching PF-04191834 placebo tablets to be administered BID for two weeks
Study NCT01492608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
Study NCT01492608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium sulphate
Description: Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
Study NCT01147458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen placebo
Description: Matching naproxen placebo tablets to be administered BID for 4 weeks
Study NCT03846752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial artery access for complex PCI
Description: Complex PCI with access via radial artery using a 7 Fr. Glideslender sheath. PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
Study NCT03846752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral artery access for complex PCI
Description: Complex PCI with access via femoral artery using a 7 Fr. standard femoral sheath . PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
Study NCT05069246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nigella Sativa oil
Description: 5ml Nigella Sativa oil mixed into 5ml water prior to use and rinsed in the mouth for 3 mins and spitted out, used twice a day; morning and evening.
Study NCT05069246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: 10ml of chlorohexidine mouthwash used for 3mins and spit out, used twice a day; morning and evening.
Study NCT02177968 — intervention group
Intervention type: OTHER
Intervention: descriptive analysis of characteristics
Description: comparison between elderly fallers and non-fallers
Study NCT00082888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00082888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study NCT01263171 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Leucovorin
Study NCT01263171 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil
Study NCT01263171 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: leucovorin calcium
Study NCT01263171 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oxaliplatin
Study NCT01263171 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: adjuvant therapy
Study NCT01263171 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: neoadjuvant therapy
Study NCT01263171 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery
Study NCT01263171 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study NCT03344315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental: collagen matrix
Description: Mucograft collagen matrix combined with coronal advanced flap
Study NCT03344315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: autologous connective tissue graft
Description: Soft tissue harvesting from patient palate with coronal advanced flap
Study NCT03841071 — intervention group
Intervention type: OTHER
Intervention: ROM/CFS intervention
Description: The intervention (ROM/CFS) includes self-reported measures for adaptation to life with an ostomy and health-related quality of life, as well as patient satisfaction recorded by the clinical feedback system. The measures are electronically assessed before each clinical consultation at 3, 6, and 12 months after surgery, and annually thereafter. The scores are instantly analysed and graphically presented for use during the consultation and the patient and stoma care nurse can discuss the findings.
Study NCT00286273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trisodium citrate
Description: for regional anticoagulation of the extracorporeal CVVH circuit
Study NCT01147458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg tablet administered BID for a total of four weeks
Study NCT00286273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nadroparin
Description: for anticoagulation of the extracorporeal CVVH circuit
Study NCT03303950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT03303950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03303950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03303950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HSCT
Study NCT03303950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03652532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting
Description: During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each fast day (24 h), and consumed food ad libitum on each feed day (24 h). The fast day and feed day were repeated every other day, and the fast day occurred 3 days per week.
Study NCT03652532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.
Study NCT02967575 — intervention group
Intervention type: DEVICE
Intervention: cTDR
Description: The surgical procedure for the Triadyme-C total disc replacement corresponds to the standard surgical technique for cTDR:~* Implantation through a standard anterior cervical approach~* Midline identification~* Routine discectomy with endplate preparation and decompression~* Implant sizing and trial implantation~* Keel preparation~* Implant preparation and loading of the appropriate Triadyme-C implant~* Triadyme-C insertion, positioned as close to the midline as possible
Study NCT06381232 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study, there are no interventions.
Study NCT03829384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1944
Description: mRNA encoding Chikungunya antibody
Study NCT03829384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline